Alexandria Venture Investments

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

Tavros Therapeutics is a biotechnology company founded in 2019 and based in Durham, North Carolina. The company focuses on discovering and developing therapies for cancer, aiming to improve oncological treatment outcomes. Tavros Therapeutics is dedicated to identifying vulnerabilities within tumors, which allows for the targeted application of specific drugs in conjunction with optimal combinations. This approach is intended to enhance the effectiveness of cancer treatments and increase the potential for patient cures.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

BIOMILQ is a Durham, North Carolina-based startup founded in 2020 that specializes in producing nutritionally equivalent human breast milk using cultured human mammary cells. The company has developed a mammary biomanufacturing platform aimed at creating bioauthentic human milk ingredients that support better health outcomes for infants. By leveraging advanced technology, BIOMILQ provides an alternative for mothers and caregivers seeking a nutritious and sustainable feeding option, promoting essential aspects of infant development, including immune, gut, and neurological health. The company's innovative approach empowers families with a comprehensive solution for early-life nutrition.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Invaio Sciences, Inc. is a multi-platform technology company headquartered in Cambridge, Massachusetts, with additional offices in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Established in 2016, the company focuses on harnessing advanced sciences to address critical challenges in agriculture, nutrition, and the environment. Invaio's innovative technologies aim to reduce pesticide usage globally by enhancing the understanding of insect physiology and interdependent natural systems. By developing solutions that are both effective against pests and safe for beneficial species, Invaio seeks to create a positive impact on agriculture and human and animal health, positioning itself at the forefront of transformative practices in these fields.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. The company specializes in developing multi-functional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide aimed at crop protection, and BN2266, a fungicide that targets mRNA processing. Additionally, the company is working on a dual-function nematicide-fungicide for root protection and endo-parasiticides designed to overcome resistance. Boragen's innovative synthetic chemistry platform focuses on creating next-generation fungicides that support sustainable farming by minimizing the risk of fungicide resistance and reducing chemical usage while ensuring efficacy and performance.